LeonaBio, Inc. (LONA) Stock

About LeonaBio, Inc.

LeonaBio, Inc. is led by CEO Mark J. Litton, employs 26 people, headquartered in US, publicly traded since 2020.

LeonaBio, Inc. (LONA) stock trades at $4.84 with a market capitalization of $19.09M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.16, reflecting a net loss over the last twelve months, price-to-book of 0.68, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.21 and $11.91, and currently trades 59.4% below its 52-week high.

On profitability, LeonaBio, Inc. generates a return on equity (ROE) of -411.58% (negative, reflecting a net loss), return on capital employed of -250.70%.

LeonaBio, Inc. by the numbers, 2018–2025

Between 2018 and 2025 LeonaBio, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-106.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-142.0M.

Borrowings held roughly flat from $1.0M to $1.0M, cash from operations was $-46.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -148.6% over five years, and was -378.6% in the most recent year.

The share price itself has compounded at -46.1% a year over five years, -34.2% over three, 177.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

LeonaBio, Inc. (LONA) — frequently asked questions